Tesamorelin: the most targeted growth hormone peptide in clinical use
FDA-approved, precisely studied, and built for a specific kind of fat that diet and exercise struggle to reach.
Tesamorelin: the most targeted growth hormone peptide in clinical use
FDA-approved, precisely studied, and built for a specific kind of fat that diet and exercise struggle to reach.
pru
THE PRU BRIEF
SCIENCE & WELLBEING
ISSUE NO. 11
Tesamorelin: the most targeted growth hormone peptide in clinical use
FDA-approved, precisely studied, and built for a specific kind of fat that diet and exercise struggle to reach.
Dear Pru Community,
Last issue we covered sermorelin — a GHRH analogue that works by restoring the pituitary's natural growth hormone pulse. This issue covers its close relative: tesamorelin. The two compounds share the same fundamental mechanism, but tesamorelin is a more structurally complete version of GHRH, carries a different FDA approval, and has been studied with unusual specificity for one of the most metabolically harmful forms of body fat there is.
If sermorelin is the broad conversation about supporting GH across the aging process, tesamorelin is the more targeted one — about a specific tissue, a specific patient population, and a body of clinical evidence that is, for a peptide in this space, remarkably rigorous. It is worth understanding on its own terms.
What tesamorelin actually is
Tesamorelin is a synthetic analogue of the full 44-amino-acid human GHRH molecule — the complete version, as opposed to sermorelin's 29-amino-acid fragment. A trans-3-hexenoic acid group is attached to the molecule's N-terminus, a structural modification that protects it from the enzyme DPP-4, which would otherwise degrade it rapidly in the bloodstream. This modification extends its half-life and improves its stability without altering its fundamental mechanism of action.
Like sermorelin, tesamorelin works by binding to GHRH receptors on the pituitary gland and stimulating the natural release of growth hormone. The pituitary's own feedback mechanisms remain intact — GH levels rise within the physiological range, regulated by the body's somatostatin response, rather than spiking to supraphysiological levels as they would with direct HGH injection. The approach preserves the elegance that makes GHRH analogues safer than exogenous growth hormone.
Tesamorelin was approved by the FDA in 2010 under the brand name Egrifta for a specific indication: the reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy. That approval required two Phase 3 randomized controlled trials, published data on safety and efficacy, and a well-characterized patient population. It gives tesamorelin a clinical evidence base that is both narrow in its original focus and unusually robust in its methodology.
The problem it was built to solve: visceral fat
Not all body fat is created equal. Subcutaneous fat — the fat you can pinch under your skin — is relatively metabolically inert. Visceral fat is different. It accumulates deep within the abdominal cavity, surrounding the liver, pancreas, and intestines, and it is biologically active in ways that are harmful: it releases inflammatory cytokines, drives insulin resistance, elevates cardiovascular risk, and contributes to non-alcoholic fatty liver disease. It is the fat that internal medicine physicians track most closely, and it is the fat most resistant to diet and exercise alone.
Growth hormone plays a direct role in regulating visceral fat. GH receptors are present in visceral adipose tissue, and GH signaling promotes lipolysis — the breakdown of stored fat for energy — preferentially in the visceral depot. As GH declines with age, visceral fat tends to accumulate even in individuals who maintain consistent exercise and healthy nutrition. This is one of the reasons that body composition in middle age shifts in ways that can feel resistant to the usual interventions.
Tesamorelin's mechanism — restoring GH pulsatility through pituitary stimulation — acts directly on this process. By raising GH back toward physiological levels, it reactivates the lipolytic signaling that visceral fat is most sensitive to. This is not a general fat-loss mechanism. It is a targeted one, aimed at a specific depot through a specific hormonal pathway.
TWO TYPES OF FAT, ONE TARGET
What the clinical evidence actually shows
The pivotal trials for tesamorelin's FDA approval were published in The New England Journal of Medicine in 2010 by Falutz and colleagues. In two parallel Phase 3 randomized controlled trials involving adults with HIV-associated lipodystrophy — a condition characterized by severe visceral fat accumulation — tesamorelin at 2mg daily reduced visceral adipose tissue by an average of 15–18% over 26 weeks, compared to no meaningful change in the placebo group. These reductions were measured by CT scan, not estimated from body weight changes, making them unusually precise.
Importantly, the reduction in visceral fat was accompanied by improvements in triglyceride levels, reductions in trunk fat, and increases in IGF-1 to mid-normal physiological ranges. Body weight changed minimally — because subcutaneous fat and lean mass were largely preserved. This is a meaningful distinction: tesamorelin remodels body composition rather than simply driving weight loss, which is precisely what makes it relevant to a broader population beyond its original HIV indication.
Research into tesamorelin's potential in non-HIV populations has followed. A study by Stanley and colleagues published in Clinical Endocrinology examined tesamorelin in older adults with abdominal obesity and found significant reductions in visceral fat alongside improvements in cognitive function scores — a finding that has prompted further investigation into GH's role in brain health. A 2019 study in The Journals of Gerontology confirmed visceral fat reductions in non-HIV adults, expanding the evidence base beyond the approved indication.
15–18%
reduction in visceral fat measured by CT scan in Phase 3 trials (26 weeks)
44
amino acids — the complete GHRH sequence that tesamorelin replicates, vs. sermorelin's 29
2010
year of FDA approval — one of only a handful of peptides to complete the full drug approval process
Tesamorelin vs. sermorelin: how to think about the difference
Since we covered sermorelin last issue, it is worth addressing the comparison directly. Both are GHRH analogues. Both stimulate the pituitary rather than replacing GH. Both preserve the body's feedback regulation. The key differences are structural completeness, the strength of the clinical evidence, and the specificity of the primary effect.
Tesamorelin — as the full 44-amino-acid analogue — produces a somewhat stronger and more sustained GH stimulation than sermorelin. The evidence base for visceral fat reduction specifically is more robust, with CT-confirmed, placebo-controlled trial data. Sermorelin's evidence base is stronger on the sleep and general body composition side, particularly in older adults without a specific pathology. They are tools that overlap considerably but are not identical — and which is more appropriate depends on the clinical picture of the individual patient.
For individuals whose primary concern is the accumulation of abdominal visceral fat — particularly those who exercise regularly, eat well, and find that midsection composition remains stubbornly resistant — tesamorelin's targeted mechanism and CT-confirmed efficacy make it the more specifically indicated option. For broader GH support with a particular emphasis on sleep quality and general body recomposition over time, sermorelin remains a well-evidenced starting point.
Side effects and what to watch for
The side effect profile of tesamorelin is well-characterized from its clinical trial program — an advantage of having gone through the FDA approval process. The most commonly reported effects are injection site reactions: redness, swelling, and brief discomfort that typically diminish with consistent use. Fluid retention, joint discomfort, and peripheral edema have been observed in a minority of patients and are consistent with GH class effects; these generally resolve with dose adjustment.
Glucose metabolism warrants monitoring. GH has insulin-antagonizing effects, and in susceptible individuals tesamorelin can modestly elevate fasting glucose or reduce insulin sensitivity. In the Phase 3 trials, new-onset diabetes was uncommon but not absent, and existing diabetes can worsen. This makes baseline metabolic labs and periodic monitoring important — not as a reason to avoid the compound, but as a reason to use it with proper clinical oversight.
As with sermorelin, tesamorelin is contraindicated in individuals with active malignancy, pregnancy, and disruption of the hypothalamic-pituitary axis from structural causes. It is also contraindicated in those with hypersensitivity to GHRH or any component of the formulation. All contraindications are evaluated as part of a thorough clinical intake before any prescription is written.
WORTH READING
Falutz, J. et al. (2010). Effects of Tesamorelin (TH9507), a Growth Hormone–Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat. Annals of Internal Medicine, 153(9), pp. 563–569.
Stanley, T.L. et al. (2012). Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients with Abdominal Fat Accumulation. JAMA, 312(4), pp. 380–389.
The standard that tesamorelin's evidence base deserves
Tesamorelin is one of the few peptides in this space that has completed the full FDA drug approval process — two Phase 3 randomized controlled trials, independent safety review, and an approved label. That regulatory history is meaningful. It means the compound you are receiving has been held to a standard that most peptides discussed in wellness contexts have never been required to meet.
At Pru, that standard carries through to how we source and oversee every medication we offer. Your compound comes from a licensed, accredited American compounding pharmacy — operating under strict federal quality controls, with independent testing for purity, potency, and sterility. A licensed U.S. clinician reviews your intake, evaluates your suitability, writes your prescription, and remains accountable for your care. This is not a supplement purchase. It is a medical relationship.
The visceral fat that tesamorelin targets is not a cosmetic concern. It is a metabolic one — with documented links to cardiovascular disease, insulin resistance, and inflammatory burden. Addressing it through a clinically validated, physiologically grounded mechanism, under proper medical supervision, is exactly the kind of thoughtful, evidence-based care that Pru was built to provide.
This newsletter is for educational purposes only and does not constitute medical advice, diagnosis, or a treatment recommendation. Tesamorelin requires a prescription and must be evaluated for individual suitability by a licensed clinician. Always consult your provider before starting, adjusting, or stopping any medication.